PR Newswire Clinical TrialsOriginal article
ALZpath Broadens Strategic Agreement with Alamar Biosciences to Advance Clinical Diagnostics for Alzheimer's Disease
PartnershippTau217 antibodyPositive
AI Analysis
Summary
ALZpath expanded its strategic agreement with Alamar Biosciences, granting Alamar commercial rights to use ALZpath's proprietary pTau217 antibody in blood-based diagnostic tests for Alzheimer's disease clinical use.
Outcome Details
Expanded strategic agreement granting Alamar commercial rights to utilize ALZpath's proprietary pTau217 antibody in blood-based diagnostic tests for clinical use
Importance:6/10
Sentiment:
0.60
diagnosticpartnershiplicensingAlzheimer'sblood testbiomarker
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 23, 2026 12:30 PM